HEALTHCARE

Fiscal 2018 Performance

Fiscal 2018 P

erform

anceS

ales O

fficesS

ales O

ffices

Favorable sales of hyperuricemia and gout treatment FEBURICAlthough the following drugs have been affected by drug price revisions in the Japanese market, sales grew steadily for FEBURIC, for hyperuricemia/ gout treatment, the transdermal absorption-type analgesic/anti- inflammatory agent LOQOA Tape and Somatuline®* for treatment of acromegaly, pituitary gigantism and neuroendocrine tumors.

* Somatuline® is the registered trademark of Ipsen Pharma, France.

Solid rental volume for home oxygen therapyIn the home oxygen therapy (HOT) market, we enhanced the product lineup of the portable oxygen concentrators (Hi-Sanso Portable α and Hi-Sanso Portable α II), and we maintained a high level of rental units. Also, in the home continuous positive airway pressure (CPAP) market for sleep apnea syndrome treatment, our rental volume grew steadily, with promotion of NemLink, which monitors the operating status of devices using a mobile phone network, and the sleep evaluation device SAS-2100.

While a difficult business environment continues for companies developing new drugs, due to drug price revisions and growth in the generic drug market, the Teijin Group has developed a new drug, febuxostat, for treatment of hyperuricemia and gout, for the first time in 40 years worldwide. We have established a top market share in Japan, and we expect further sales expansion as a driving force for business growth. It is on the market in 78 countries and regions as of the end of June 2019.

In Japan, the Teijin Group was a pioneer in home oxygen therapy (HOT) services. Teijin’s strengths are its customer base, the largest in the sector, and its extensive domestic structure, which can support patients 24 hours a day, 365 days a year. Teijin provides home healthcare services to approx. 450,000 patients inside and outside of Japan. We have also secured the top level share in Japan for the rapidly growing market for continuous positive airway pressure (CPAP) ventilators for the treatment of sleep apnea syndrome (SAS), as well as with our HOT services.

▶ 70 sales offices in Japan

▶ 65 sales offices in Japan

■ Healthcare Business Group

Pharmaceuticals

Home Healthcare

Business Opportunities

Business Opportunities

Countries or regions where the Teijin Group has business alliances

78

Hyperuricemia and gout treatments

Top share* in Japan* Copyright©2019 IQVIA.

Source: IQVIA Japan Pharmaceuticals Market Statistics, April 2018–March 2019 Unautho-rized reproduction is strictly prohibited.

* Estimated from external reports and Teijin’s rental volume

Number of users in Japan and overseas

Approx. 450,000

Therapeutic oxygen concen­trators for HOT, and CPAP ventilators for the treatment of SAS

Top level share* in Japan

Medium- and Long-Term Strategies

We will strive to capture synergies between both the pharmaceuticals and home healthcare businesses. Our goal is to help to enhance the quality of life (QOL) of our patients

PharmaceuticalsSales of febuxostat, a treatment for hyperuricemia and gout, have been increasing steadily in Japan. Aiming to maximize earnings from febux-ostat, we will work to raise disease awareness and to boost recognition of the importance of treatment, striving to absorb the impact of downward revisions to drug prices. In drug discovery research, we will continue working to expand drug discovery, enhancing technologies in nuclear receptor drug discovery, mac-rocyclic and constrained peptide drug discovery, and focusing on advanced medical materials based on the integration of materials and healthcare technologies. We will also continue to promote alliances on a global scale.

Home HealthcareAlthough there was an impact in fiscal 2018 from revisions to medical fees, we will continue to strengthen the base of the Home Healthcare field by striving to further increase rental volume of HOT and CPAP devices. This will be done primarily by enhancing the functionality of these devices, bol-stering support systems and upgrading and expanding the product lineup. VitalLink is a multidisciplinary collaboration and information sharing system used by medical professionals as a tool to support comprehensive community healthcare. We have made steady progress on signing agree-ments with general practitioners directly or through medical associations. In 2018, the number of VitalLink users reached more than 2,000.

■ Pipeline

Area Code No. Target DiseaseClinical Development Phase

Phase 2 Phase 3 Filed Approval/Launch

Bone and joint disease

ITM-058 OsteoporosisNT 201 Upper limb/lower limb spasticityKTP-001 Lumbar disc herniation

Respiratory disease PTR-36 Bronchial asthma

Cardiovascular and metabolic disease

TMX-67 (PRC) Hyperuricemia and goutSTM-279 ADA deficiencyITM-014T Thyroid stimulating hormone-secreting pituitary tumorsTCF-12 Chronic kidney diseaseTMX-049 Hyperuricemia and goutTMX-049DN Diabetic nephropathy in Type 2 diabetesTMX-67HK Hyperuricemia and gout in children

Others

GGS-CIDP Chronic inflammatory demyelinating polyneuropathyGGS-ON Optic neuritisGGS-MPA Microscopic polyangiitisJTR-161 Acute cerebral infarction

* As of the end of June 2019* Approval/launch is described in the last year

SECTION 3

BUSINESS STRATEGY

Healthcare Business Field

While providing unique medical solutions through synergies between “pharma­ceutical business” and the “home healthcare business” and also through fusion with “material technology,” we have entered non­insurance medical areas such as nursing and prevention of illness. We will develop comprehensive healthcare services that meet the needs of society.

Akihisa NabeshimaExecutive Officer, Member of the BoardPresident, Healthcare Business of Teijin Group

S W O T0

20

10

30

40

50

0

10

20

30

40

50

(Right scale)⎯ ROIC

(based on operating income)

(Left scale)■ EBITDA

(FY)’19(Outlook)

’18’170

60

120

180

(FY)’19(Outlook)

’18’170

10

20

30

40

(FY)’19(Outlook)

’18’17

In­house sales and marketing power for the

global market

Product creativity focusing on unmet medical needs, a sales base built on pharmaceuticals and home healthcare, high­quality services

centered on patients, and technology utilization of materials and IT

Growing needs for regional comprehensive care and

home medical care, needs in prevention of illness and rising health consciousness

Revision of drug prices and medical costs through a domestic medical cost containment policy

Increase in research and development costs for new drugs

EBITDA (Billions of yen)ROIC (based on operating income) (%)

Net Sales (Billions of yen) Operating Income (Billions of yen) SWOT Analysis

TEIJIN LIMITED INTEGRATED REPORT 201972 TEIJIN LIMITED INTEGRATED REPORT 2019 73